Sign up
Pharma Capital

'We have a great portfolio of products and high hopes', says Integumen's Declan Service

Declan Service, chief executive of Integumen (LON:SKIN) talks to Proactive as the personal health care company begins trading on AIM.

The funds raised, £2.25mln, will primarily enable the Company to fund the development and sales and marketing of its products as well as providing working capital.

Service says they have a well-defined strategy and are now focused on further developing their products and commercialisation.

 

View full SKIN profile

Integumen Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.